Steven Lynch, MD
Urology · Salt Lake City, UTNPI 1578677803
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,891 of the $7,594 with a category attached, or 64.4%. Boston Scientific accounts for 70.0% of it on its own, with 9 other manufacturers making up the rest.
Across 130 payments — averaging $58.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$5K
- Procept Biorobotics Corporation$1K
- Bluewind Medical$781
- Laborie Medical Technologies Corp.$237
- Johnson & Johnson$70
- Pfizer$40
- plus $54 from 4 others
What the payments were for
- Travel & lodging$2,65235%
- Food & beverage$4,89164%
- Education$511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 99 | $5,317 |
| Procept Biorobotics Corporation | 11 | $1,097 |
| Bluewind Medical | 7 | $781 |
| Laborie Medical Technologies Corp. | 3 | $237 |
| Johnson & Johnson | 3 | $70 |
| Pfizer | 1 | $40 |
| Medtronic | 1 | $14 |
| Myriad Genetic Laboratories, Inc. | 1 | $14 |
| Tris Pharma Inc | 1 | $14 |
| Travere Therapeutics, Inc. | 3 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$1,109
- GENERAL - THERAPIES$634
- REVI$525
- AquaBeam Robotic System$517
- LithoVue$373
- AQUABEAM SYSTEM$296
How this compares
$7,594 in reported general payments places this provider in the 70th percentile of 96 urology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 81 | $49,663 |
| Tamsulosin Hcl | 324 | $6,402 |
| Finasteride | 272 | $4,636 |
| Solifenacin Succinate | 134 | $4,252 |
| Potassium Citrate ErPotassium Citrate | 49 | $3,221 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 112 | $2,592 |
| Febuxostat | 12 | $1,519 |
| Bethanechol Chloride | 22 | $1,347 |
| Oxybutynin Chloride ErOxybutynin Chloride | 70 | $1,242 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 19 | $1,202 |
| Silodosin | 15 | $1,147 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 48 | $459 |
| Cefdinir | 26 | $452 |
| Cephalexin | 34 | $333 |
| Testosterone Cypionate | 13 | $278 |
Paid to pharmacies, not to this prescriber.
Other urology in Salt Lake City
- William BrantSalt Lake City$290K
- Benjamin McCormickSalt Lake City$67K
- Richard MaternSalt Lake City$58K
- Akhil SajiSalt Lake City$49K
- Stephen SummersSalt Lake City$15K
- Jeremy MyersSalt Lake City$15K
- Gary JohnsonSalt Lake City$15K
- Sara LenherrSalt Lake City$12K
- Mitchell BassettSalt Lake City$10K
- Joseph ArmstrongSalt Lake City$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.